Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

GeneScan makes investment in MWG Biotech

This article was originally published in Clinica

Executive Summary

GeneScan Europe, a developer of bioanalytical testing technology based in Freiburg, Germany, has acquired a 25.1% stake in fellow German firm MWG Biotech, the troubled genomics technology provider, writes Stefan Fritsch*. GeneScan has purchased shares from two major shareholders, and E2m ($2.5m) worth of convertible bonds. Furthermore, GeneScan's Dutch parent, Eurofins Ventures, has bought an additional 2 million bonds directly from MWG.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT054065

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel